---
title: Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
date: '2024-05-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38791079/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240525190013&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Recent advances in the treatment of gastric cancer (GC) with chemotherapy,
  immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some
  improvement in survival outcomes; however, metastatic GC remains a lethal malignancy
  and amongst the leading causes of cancer-related mortality worldwide. Importantly,
  the ongoing molecular characterisation of GCs continues to uncover potentially actionable
  molecular targets. Among these, aberrant FGFR2-driven signalling, predominantly
  ...
disable_comments: true
---
Recent advances in the treatment of gastric cancer (GC) with chemotherapy, immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some improvement in survival outcomes; however, metastatic GC remains a lethal malignancy and amongst the leading causes of cancer-related mortality worldwide. Importantly, the ongoing molecular characterisation of GCs continues to uncover potentially actionable molecular targets. Among these, aberrant FGFR2-driven signalling, predominantly ...